Company intelligence / Profile preview

Airtransa

Cambridge, Massachusetts, United Statesairtransa.net ↗

Ownership: Private
Development stage: Other

Overview

AIRNA is advancing a proprietary RNA editing platform with its lead candidate, AIR‑001, targeting alpha‑1 antitrypsin deficiency. The company has raised significant funding and plans to enter clinical trials in late 2025. Early preclinical data supports the potential of their approach to correct disease-causing mutations at the RNA level, aiming for functional cures in rare and common diseases.

Therapeutic areas: CardiovascularRare Diseases
Modalities: RNA therapyGene editing
Industry: Biotech

Partnerships

none disclosed yet—company open to future partnerships with larger pharma companies.

Beyond the preview

Go deeper on Airtransa.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Airtransa.

Explore the full profile